In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Clinical efficiency of macitentan in patients with pulmonary hypertension. our experience in argentina

Session Poster Session 1

Speaker Adrian Lescano

Congress : Heart Failure 2017

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Pulmonary Hypertension
  • Session type : Poster Session
  • FP Number : P575

Authors : H Gomez Santa Maria (Buenos Aires,AR), A Ferro (Buenos Aires,AR), G Bortman (Buenos Aires,AR), V Gregorietti (Florencio Varela,AR), N Atamanuk (Buenos Aires,AR), N Carusso (Buenos Aires,AR), A Lescano (Buenos Aires,AR)

H Gomez Santa Maria1 , A Ferro1 , G Bortman2 , V Gregorietti3 , N Atamanuk4 , N Carusso2 , A Lescano1 , 1Finochietto Clinic - Buenos Aires - Argentina , 2Sanatorium Mitre - Buenos Aires - Argentina , 3Hospital El Cruce - Florencio Varela, Buenos Aires - Argentina , 4Hospital Fernandez - Buenos Aires - Argentina ,

European Journal of Heart Failure ( 2017 ) 19 ( Suppl. S1 ), 147

Introduction. Pulmonary Hypertension (PH) is a disease characterized by an increase in pulmonary resistances that leads to right heart disfunction, heart failure and death. There are multiple associated pathophysiological mechanisms that are used as therapeutic targets. Macitentan (M) is a non-selective inhibitor of endothelin receptors, which has demonstrated clinical benefits in morbidity and mortality in a Phase III study. (Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension SERAPHIN trial).

Objective: To describe the clinical efficacy in our population of Macitentan in PH patients.

MATERIAL AND METHODS: A prospective, consecutive, open, phase IV registry of patients with PH who started treatment with M (Opsumit MR) in Argentina, from March 2015 to November 16, was performed. We included those p who received M for at least 6 months or presented an event. Baseline characteristics, functional class (FC), 6-minute gait test (TM6M), adverse effects and survival were determined according to the recommendations of the national and international guidelines, at baseline and at 6 month. Clinical efficacy was determined by the improvement in FC from III-IV (advanced) to FC I-II (not advanced), and improvement in 6MWT> 15%. The data was loaded into an Excel database and evaluated with the Bioestat 5.0 program. The normality of the sample was analyzed by the D'Agostino-Pearson test. In relation to the distribution, the t test was used for quantitative variables, ChiĀ² for qualitative and McNemar test for paired variables. A p value of <0.05 was defined as a significant difference between baseline and 6 months.

Results: We included 151 p, 74% women, the average of age was 46 years (28-63) and 98.4% had HP group 1. 98.6% received M 10 mg and 1.4% 5 mg. At baseline, functional class evaluation presented the following distribution: FC I 2.4%, II 19.4%, III 65.3% and IV 12.9% (advanced FC 78.2%). The mean baseline TM6M was 321 m (250-400). At 6 months FC I was 13.5%, II 62.2% and III 24.3% (advanced FC 24.3%), with significant statistical benefit (p <0.001). The mean TC6M reached 397.2 m (320-467), an increase of 24%, with a significant difference (p <0.0001, 95% IC-533-51.6).

Conclusion: In our PH registry, administration of Macitentan was associated with a significant benefit in achieving the objectives of functional class improvement and the distance reached in the 6MWT (76 meters), at 6 months. These data are in agreement with those obtained in the randomized study SERAPHIN.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are